Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 65

Personalized brain- circuit based approach to pramipexole in depression

Official title: Stratified Pharmacological Approaches for Regulating Circuit-Level Effects Study

Run by Stanford University · NCT07022405 · Data updated 2026-11-12

This study tests whether pramipexole helps people with major depressive disorder based on specific brain circuit activity.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment60 (estimated)
SponsorStanford University
Academic / other
Locations1 site (Palo Alto, California)
StatusRecruiting
StartedJanuary 23, 2026
Main results expectedAugust 2030
Study endsAugust 2030
Registry record updatedMay 15, 2026
Trial IDNCT07022405 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18-65 with current or recurrent nonpsychotic MDD who can complete an fMRI and consent to the protocol.

Probably not a fit

Patients whose depression does not show circuit-based responsiveness to pramipexole or who cannot complete MRI screening may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this phase 2 trial, researchers will use an 8-week course of pramipexole to see how patients with depression respond and whether brain circuit function predicts who benefits. Participants will undergo a one-time, non-invasive fMRI assessment, complete in-scanner tasks, and provide mood and cognitive information, followed by weekly remote check-ins during treatment and a 2-week taper. The goal is to identify circuit-based factors that relate to treatment response and to move toward personalized medication choices. The study is conducted at Stanford with collaboration from NIMH and is open to adults 18-65 meeting criteria for current or recurrent nonpsychotic MDD.

Why it matters

Potential benefit: If successful, the study could lead to more tailored use of pramipexole for depression based on brain circuitry.

How similar studies have gone: Other trials have explored circuit-informed approaches in mood disorders, but this specific brain-circuit stratification with pramipexole is a newer, exploratory strategy.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18-65 years old (inclusive)
* Fluent and literate in English, with non-impaired intellectual abilities to ensure adequate comprehension of the task instructions.
* Willing to provide written, informed consent.
* Functional magnetic resonance imaging (fMRI) scanning eligibility. All participants will need to successfully complete the screening forms at the Stanford Center for Cognitive and Neurobiological Imaging (CNI).
* Patient Health Questionnaire-8 (PHQ-8) \>/= 10
* Meet the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria for current or recurrent nonpsychotic Major Depressive Disorder (MDD) established by the Mini International Neuropsychiatric Interview (MINI)

Exclusion Criteria:

* Suicidality with active plan or as determined clinician judgment
* Current or lifetime history of medical illness or brain injury that may interfere with assessments as determined by clinician judgment
* Severe impediment to vision, hearing, and/or hand movement likely to interfere with ability to complete the assessments, or is unable and/or unlikely to follow the study protocols as determined by clinician judgment
* Pregnant, breastfeeding or unwilling or unable to use adequate birth control throughout the study
* History of non-responsive depression to dopamine agonists
* Any contraindication to being scanned in the 3.0T fMRI scanner, such as a cardiac pacemaker or implanted device that has not been cleared for scanning
* Previous or current DSM-5 bipolar disorder (I, II, not otherwise specified), schizophrenia spectrum or other psychotic disorders, or psychosis or as determined by clinician judgment
* Previous or current diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
* Meeting DSM-5 criteria for current Obsessive-Compulsive Disorder (OCD) or eating disorder
* Meeting DSM-5 criteria for alcohol use disorder or substance use disorder within the last 12 months
* Clinically significant presence/history of impulsive-compulsive behaviors or control disorder including but not limited to gambling disorder within the last 12 months.
* Current use or use of psychotropic medication within the past month. (If the participant's usual treating clinician agrees with discontinuing the medication, participants may enroll after tapering off the medication under the supervision of either their usual clinician or the study clinician. A washout period of 5 half-lives-or a different duration as determined by the study clinician-must be completed before the first scan.)
* Concurrent participation in other intervention or treatment studies

Where it's running

  • Stanford University
    Palo Alto, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.